Brief: Valneva Receives First Marketing Authorization For Ixchiq® In Brazil
14/04/2025 16:51
April 14 (Reuters) - Valneva SE VLS.PA: VALNEVA SAYS BRAZILIAN HEALTH REGULATORY AGENCY (ANVISA) HAS GRANTED MARKETING AUTHORIZATION TO ITS SINGLE-DOSE VACCINE IXCHIQ VALNEVA RECEIVES FIRST MARKETING AUTHORIZATION FOR IXCHIQ® IN A CHIKUNGUNYA ENDEMIC COUNTRY APPROVAL ENABLES INITIATION OF LARGE-SCALE CLINICAL TRIALS OF IXCHIQ® IN BRAZIL, INCLUDING COMMITTED PHASE 4 CLINICAL TRIALS Source text: nGNX5cTyvX Further company coverage: VLS.PA (Gdansk Newsroom) ((gdansk.newsroom@thomsonreuters.com; +48 58 7785110;))
Recent news on Valneva SE
See all newsBrief: UK MHRA Withdraws Marketing Authorisation for Ixchiq Chikungunya Vaccine After Safety Review
Valneva falls as UK regulator revokes Ixchiq vaccine authorisation
Brief: Valneva Provides Update On Ixchiq® In The United Kingdom
Valneva surges after EU regulator validates Lyme disease vaccine application
Brief: Pfizer And Valneva's Lyme Disease Vaccine Candidate Marketing Authorization Application Validated By European Medicines Agency